This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
The results were extensively presented and an incremental approach was appropriately used to combine the costs and benefits of the two treatments. Appropriate tools were used to assess uncertainty, and the methods and results were clearly reported. The authors provided clear details of the structure and assumptions of the model. They acknowledged some limitations to their analysis mainly due to the need for simplifications in the model, but these appear to have been addressed in the sensitivity analysis. The results were specific to the USA, but might be relevant to other settings with similar relative drug prices.
Concluding remarks:
The analysis relied on the results of a clinical trial. The cost-effectiveness methods were valid and key areas of uncertainty were investigated. The authors' conclusions appear to be robust.
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